ENOV Stock — Enovis Corp.

Enovis Corp. (ENOV)

Updated October 16, 2026.

ENOV is a Stock. Total return is -45.8% over the past 18.4 years, 714.0 points behind SPY at 668.2%.

Enovis Corporation is a medical technology company that develops and manufactures orthopedic and surgical solutions across two segments: Prevention and Recovery products such as bracing, therapy systems, and pain management devices; and Reconstructive products including joint replacement implants, instrumentation, and limb reconstruction solutions. The company distributes its products to healthcare professionals and patients through direct sales, independent distributors, and other channels. Enovis does not currently have an established regular distribution schedule.

ENOV performance versus SPY

Price and return data through 2026-10-16.

Total return is -45.8% over the past 18.4 years, 714.0 points behind SPY at 668.2%. Over the past year its total return — price change plus distributions reinvested — is -37.2%. Its deepest 1-year drawdown was 47.0%.

ENOV key facts

Asset type

Stock

Asset class

Equity

Inception date

05/08/2008

Distribution frequency

None

Last close

$19.59 (as of 2026-10-16)

Market cap

$1,129,745,387

Average volume

1340961.0

Beta

1.483

Payout ratio

0.0%

Forward P/E

4.6404

EPS

$-19.23

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

ENOV risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 47.0%.

Who may consider ENOV — and who may not

It is a weaker fit for investors who need monthly cash flow (ENOV does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on ENOV

• All tickers starting with E

Tagged: Healthcare.

Frequently asked questions